Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Sagimet Biosciences (NASDAQ:SGMT) is projected to release its Q2 2025 earnings on August 13th, expecting to report earnings of ($0.57) per share.
• Analysts have recently set new price targets for Sagimet, with estimates ranging from $26.83 to $28.00, reflecting a consensus buy rating.
• Insider transactions indicate significant share sales, with CEO David Happel selling 65,478 shares, reducing his ownership by 8.67%.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Sagimet Biosciences to post earnings of ($0.57) per share for the quarter.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.23. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Price Performance

Sagimet Biosciences stock traded up $0.21 during trading hours on Wednesday, hitting $9.17. The company had a trading volume of 464,770 shares, compared to its average volume of 817,033. The firm has a 50-day moving average of $7.85 and a 200 day moving average of $5.02. The firm has a market cap of $281.24 million, a PE ratio of -5.21 and a beta of 3.37. Sagimet Biosciences has a one year low of $1.73 and a one year high of $11.41.

Insider Buying and Selling

In other news, General Counsel Elizabeth Rozek sold 10,780 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $9.13, for a total value of $98,421.40. Following the completion of the transaction, the general counsel directly owned 183,726 shares in the company, valued at approximately $1,677,418.38. This represents a 5.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eduardo Bruno Martins sold 8,277 shares of the company's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $9.13, for a total value of $75,569.01. Following the completion of the transaction, the insider directly owned 106,936 shares of the company's stock, valued at $976,325.68. This represents a 7.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 84,535 shares of company stock worth $771,805 in the last ninety days. 14.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sagimet Biosciences

An institutional investor recently bought a new position in Sagimet Biosciences stock. NewEdge Advisors LLC purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 32,290 shares of the company's stock, valued at approximately $105,000. NewEdge Advisors LLC owned 0.11% of Sagimet Biosciences at the end of the most recent quarter. Institutional investors own 87.86% of the company's stock.

Analysts Set New Price Targets

SGMT has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on Sagimet Biosciences in a report on Thursday, July 24th. They set a "buy" rating and a $28.00 target price for the company. Jones Trading lifted their price objective on Sagimet Biosciences from $15.00 to $27.00 and gave the company a "buy" rating in a report on Friday, June 6th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $26.83.

About Sagimet Biosciences

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.